

REFERENCES

1. Talme T, Schultzberg M, Sundqvist K-G, Marcusson JA. Colocalization of somatostatin- and HLA-DR-like immunoreactivity in dendritic cells of psoriatic skin. *Acta Derm Venereol* 1997; 77: 338–342.
2. Talme T, Schultzberg M, Sundqvist K-G, Marcusson JA. Somatostatin- and factor XIIIa-immunoreactive cells in psoriasis during clobetasol propionate and calcipotriol treatment. *Acta Derm Venereol* 1999; 79: 44–48.
3. Wollina U, Mahrle G. Epidermal Merkel cells in psoriatic lesions: immunohistochemical investigations on neuroendocrine antigen expression. *J Dermatol Sci* 1992; 3: 145–150.
4. Wollina U. Somatostatin and psoriasis. *Acta Derm Venereol* 1999; 78: 226.
5. Masuda T, Ikeda S, Tajima K, Kawamura T. Neuron-specific enolase: a specific marker for Merkel cells in human epidermis. *J Dermatol* 1986; 13: 67–69.
6. Fantini F, Johansson O. Neurochemical markers in human cutaneous Merkel cells. *Exp Dermatol* 1995; 4: 365–371.
7. Coons AH. Fluorescent antibody methods. In: Danielli JF (editor). *General cytochemical methods*. Vol 1. New York: Academic Press, 1958: 399–422.
8. Matt LH, Kingston TP, Lowe NJ. Treatment of severe psoriasis with intravenous somatostatin. *J Dermatol Treatm* 1989; 181: 81–82.
9. Payan DG, Hess CA, Goetzl EJ. Inhibition by somatostatin of the proliferation of T lymphocytes and molt-4 lymphoblasts. *Cell Immunol* 1984; 84: 433–438.
10. Qin Y, Ertl T, Groot K, Horvath J, Cai R-Z, Schally A. Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. *Int J Cancer* 1995; 60: 694–700.

Accepted February 7, 1999

Toomas Talme¹ and Marianne Schultzberg²
¹Department of Dermatology, Huddinge University Hospital, SE-141 86 Huddinge and ²Department of Clinical Neuroscience, Geriatric Medicine, Karolinska Institute, Novum, Huddinge, Sweden.

Inverse Psoriasis Induced by Terbinafine

Sir,

Terbinafine is an allylamine, it is a lipophilic compound used for the treatment of onychomycoses and other fungal infections. Adverse effects are reported in 10.4% of patients, with cutaneous reactions in 2.7% (1). These include severe reactions, such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (1, 2), cutaneous lupus erythematosus (3) and acute generalized exanthematous pustulosis (4). Recently terbinafine has been linked with the occurrence of psoriasis *de novo* or its exacerbation (1, 2, 5). We report here the first case of inverse psoriasis induced by terbinafine.

CASE REPORT

A 74-year-old woman, suffering from a long history of fingernail dystrophy, was treated with oral terbinafine, 250 mg/day, by her general practitioner. Onychomycosis was diagnosed clinically. No other skin lesions were noted at that time. Two weeks after the beginning of the treatment, she developed erythematous and scaling lesions of the groin, vulva, submammary folds, axillae and navel. The whole scalp showed red and scaling patches of varying size. Pitting, subungual hyperkeratosis and onycholysis of the fingernails were present. All features were consistent with a diagnosis of inverse psoriasis associated with fingernails and scalp psoriasis. There was no personal history of psoriasis, but her first cousin was affected with psoriasis. She was on no other medications. Routine blood screening was negative or within normal limits. Terbinafine was discontinued and this was followed by rapid improvement of the psoriasis which, with only topical drugs, almost completely disappeared in 2 weeks, except for the fingernail dystrophy.

CONCLUSION

In this case, a probable psoriatic onychodystrophy, misdiagnosed as onychomycosis, without mycological investigation and treated with terbinafine, induced an inverse psoriasis. We emphasize the importance of mycological investigation before commencing therapy for suspected onychomycosis. This case and other reports suggest prudence when terbinafine is used for onychomycosis or dermatophytosis in patients with coexistent psoriasis.

REFERENCES

1. Gupta AK, Sibbald RG, Knowles SR, Lynde CW, Shear NH. Terbinafine therapy may be associated with the development of psoriasis *de novo* or its exacerbation: four case reports and a review of drug-induced psoriasis. *J Am Acad Dermatol* 1997; 36: 858–862.
2. Wilson NJE, Evans S. Severe pustular psoriasis provoked by oral terbinafine. *Br J Dermatol* 1998; 139: 168.
3. Murphy M, Barnes L. Terbinafine-induced lupus erythematosus. *Br J Dermatol* 1999; 138: 708–709.
4. Condon CA, Downs AMR, Archer CB. Terbinafine-induced acute generalized exanthematous pustulosis. *Br J Dermatol* 1998; 138: 709–710.
5. Papa CA, Miller OF. Pustular psoriasiform eruption with leukocytosis associated with terbinafine. *J Am Acad Dermatol* 1998; 39: 115–117.

Accepted February 1, 1999

Paolo Pauluzzi and Nicola Boccucci
 Institute of Dermatology, University of Trieste, Ospedale di Cattinara, Strada per Fiume, IT-34149, Trieste, Italy.